Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)

BMC Infectious Diseases

Volumn 7, Issue , 2007, Pages

  Sader, Helio S ^a,b   Watters, Amy A ^a   Fritsche, Thomas R ^a   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG POTENCY; ENTEROCOCCUS FAECIUM; EUROPE; FRANCE; GEOGRAPHIC DISTRIBUTION; IN VITRO STUDY; IRELAND; ISRAEL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN DIFFERENCE; SWEDEN; SWITZERLAND; TURKEY (REPUBLIC); UNITED KINGDOM; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; DRUG EFFECT; ENTEROCOCCUS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PENICILLIN RESISTANCE; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; ENTEROCOCCUS; EUROPE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; VANCOMYCIN RESISTANCE;

EID: 34248513134     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-7-29     Document Type: Article

References (44)

1. Biedenbach DJ Moet GJ Jones RN Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002) Diagn Microbiol Infect Dis 2004 50 1 59-69 10.1016/j.diagmicrobio.2004.05.003 15380279
2. Edmond MB Wallace SE McClish DK Pfaller MA Jones RN Wenzel RP Nosocomial bloodstream infections in United States hospitals: A three-year analysis Clin Infect Dis 1999 29 2 239-244 10476719
3. Rice LB Antimicrobial resistance in Gram-positive bacteria American Journal of Infection Control 2006 34 5, Supplement 1 S11-S19 10.1016/ j.ajic.2006.05.220 16813977
4. NNIS National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004 Am J Infect Control 2004 32 8 470-485 10.1016/j.ajic.2004.10.001 15573054
5. Wisplinghoff H Bischoff T Tallent SM Seifert H Wenzel RP Edmond MB Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study Clin Infect Dis 2004 39 3 309-317 10.1086/421946 15306996
6. Wisplinghoff H Seifert H Tallent SM Bischoff T Wenzel RP Edmond MB Nosocomial bloodstream infections in pediatric patients in United States hospitals: Epidemiology, clinical features and susceptibilities Pediatr Infect Dis J 2003 22 8 686-691 12913767
7. Tenover FC McDougal LK Goering RV Killgore G Projan SJ Patel JB Dunman PM Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States J Clin Microbiol 2006 44 1 108-118 1351972 16390957 10.1128/JCM.44.1.108-118.2006
8. Willems RJ Top J van Santen M Robinson DA Coque TM Baquero F Grundmann H Bonten MJ Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex Emerg Infect Dis 2005 11 6 821-828 15963275
9. Mascini EM Bonten MJ Vancomycin-resistant enterococci: Consequences for therapy and infection control Clin Microbiol Infect 2005 11 Suppl 4 43-56 10.1111/j.1469-0691.2005.01164.x 15953021
10. Stevens MP Edmond MB Endocarditis due to vancomycin-resistant enterococci: Case report and review of the literature Clin Infect Dis 2005 41 8 1134-1142 10.1086/444459 16163631
11. Sader HS Streit JM Fritsche TR Jones RN Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: Results of the Daptomycin Surveillance Programme (2002-2004) Clin Microbiol Infect 2006 12 9 844-852 10.1111/j.1469-0691.2006.01550.x 16882289
12. Package Insert Cubicin (daptomycin for injection). Lexington MA. (Cubist Pharmaceuticals, Inc). Available at http://www.cubicin.com/ 2006_full_pi.pdf. Accessed on June 28, 2006. 2006 http://www.cubicin.com/ 2006_full_pi.pdf
13. Fenton C Keating GM Curran MP Daptomycin Drugs 2004 64 4 445-55; discussion 457-8 10.2165/00003495-200464040-00009 14969579
14. Steenbergen JN Alder J Thorne GM Tally FP Daptomycin: A lipopeptide antibiotic for the treatment of serious Gram-positive infections J Antimicrob Chemother 2005 55 3 283-288 10.1093/jac/dkh546 15705644
15. Fuchs PC Barry AL Brown SD Daptomycin susceptibility tests: Interpretive criteria, quality control, and effect of calcium on in vitro tests Diagn Microbiol Infect Dis 2000 38 1 51-58 10.1016/S0732-8893(00)00164-4 11025184
16. Silverman JA Perlmutter NG Shapiro HM Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus Antimicrob Agents Chemother 2003 47 8 2538-2544 166110 12878516 10.1128/AAC.47.8.2538-2544.2003
17. Carpenter CF Chambers HF Daptomycin: Another novel agent for treating infections due to drug-resistant Gram-positive pathogens Clin Infect Dis 2004 38 7 994-1000 10.1086/383472 15034832
18. Laganas V Alder J Silverman JA In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis Antimicrob Agents Chemother 2003 47 8 2682-2684 166111 12878541 10.1128/ AAC.47.8.2682-2684.2003
19. Segreti JA Crank CW Finney MS Daptomycin for the treatment of Gram-positive bacteremia and infective endocarditis: A retrospective case series of 31 patients Pharmacotherapy 2006 26 3 347-352 10.1592/ phco.26.3.347 16503714
20. Cubicin Product Information European Medicines Agency. http://www.emea.eu.int/humandocs/Humans/EPAR/cubicin/cubicin.htm. Accessed May 11, 2006. 2006 http://www.emea.eu.int/humandocs/Humans/ EPAR/cubicin/cubicin.htm
21. EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. EUCAST Technical Note on daptomycin Clin Microbiol Infect 2006 12 6 599-601 10.1111/j.1469-0691.2006.01455.x 16700717
22. Clinical and Laboratory Standards Institute M100-S16, Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. Wayne, PA: CLSI 2006
23. Pankey GA Sabath LD Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections Clin Infect Dis 2004 38 6 864-870 10.1086/381972 14999632
24. Sakoulas G Moise-Broder PA Schentag J Forrest A Moellering RC Jr. Eliopoulos GM Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia J Clin Microbiol 2004 42 6 2398-2402 427878 15184410 10.1128/JCM.42.6.2398-2402.2004
25. Asseray N Jacqueline C Le Mabecque V Batard E Bugnon D Potel G Caillon J Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy Antimicrob Agents Chemother 2005 49 2 857-859 547277 15673789 10.1128/ AAC.49.2.857-859.2005
26. Sakoulas G Gold HS Cohen RA Venkataraman L Moellering RC Eliopoulos GM Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia J Antimicrob Chemother 2006 57 4 699-704 10.1093/jac/dkl030 16464892
27. Jones RN Microbiological features of vancomycin in the 21st century: Minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains Clin Infect Dis 2006 42 Suppl 1 S13-24 10.1086/491710 16323115
28. Cosgrove SE Carroll KC Perl TM Staphylococcus aureus with reduced susceptibility to vancomycin Clin Infect Dis 2004 39 4 539-545 10.1086/ 422458 15356818
29. May J Shannon K King A French G Glycopeptide tolerance in Staphylococcus aureus J Antimicrob Chemother 1998 42 2 189-197 10.1093/jac/42.2.189 9738836
30. Sader HS Fritsche TR Jones RN Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin Antimicrob Agents Chemother 2006 50 7 2330-2336 1489799 16801409 10.1128/AAC.01491-05
31. Lundstrom TS Sobel JD Antibiotics for Gram-positive bacterial infections: Vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin Infect Dis Clin North Am 2004 18 3 651-68, x 10.1016/ j.idc.2004.04.014 15308280
32. Linden PK Moellering RC Jr. Wood CA Rehm SJ Flaherty J Bompart F Talbot GH Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin Clin Infect Dis 2001 33 11 1816-1823 10.1086/323899 11668430
33. Moellering RC Linezolid: The first oxazolidinone antimicrobial Ann Intern Med 2003 138 2 135-142 12529096
34. Landman D Quale JM Management of infections due to resistant enterococci: A review of therapeutic options J Antimicrob Chemother 1997 40 2 161-170 10.1093/jac/40.2.161 9301980
35. Schouten MA Voss A Hoogkamp-Korstanje JA Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group Antimicrob Agents Chemother 1999 43 10 2542-2546 89517 10508041
36. Livermore DM Quinupristin/dalfopristin and linezolid: Where, when, which and whether to use? J Antimicrob Chemother 2000 46 3 347-350 10.1093/jac/ 46.3.347 10980159
37. Vergis EN Hayden MK Chow JW Snydman DR Zervos MJ Linden PK Wagener MM Schmitt B Muder RR Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study Ann Intern Med 2001 135 7 484-492 11578151
38. Gonzales RD Schreckenberger PC Graham MB Kelkar S DenBesten K Quinn JP Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid Lancet 2001 357 9263 1179 10.1016/S0140-6736(00)04376-2 11323048
39. Jevitt LA Smith AJ Williams PP Raney PM McGowan JE Jr. Tenover FC In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium Microb Drug Resist 2003 9 4 389-393 10.1089/ 107662903322762833 15000746
40. Johnson AP Mushtaq S Warner M Livermore DM Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid Int J Antimicrob Agents 2004 24 4 315-319 0.1016/j.ijantimicag.2004.04.006 15380254
41. Sader HS Streit JM Fritsche TR Jones RN Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide Diagn Microbiol Infect Dis 2004 50 3 201-204 10.1016/ j.diagmicrobio.2004.07.002 15541606
42. Sader HS Fritsche TR Jones RN Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003) Diagn Microbiol Infect Dis 2005 53 4 329-332 10.1016/j.diagmicrobio.2005.07.001 16263233
43. Fluit AC Schmitz FJ Verhoef J Milatovic D Daptomycin in vitro susceptibility in European Gram-positive clinical isolates Int J Antimicrob Agents 2004 24 1 59-66 10.1016/j.ijantimicag.2003.12.014 15225863
44. Fluit AC Schmitz FJ Verhoef J Milatovic D In vitro activity of daptomycin against Gram-positive European clinical isolates with defined resistance determinants Antimicrob Agents Chemother 2004 48 3 1007-1011 353156 14982796 10.1128/AAC.48.3.1007-1011.2004